Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation

Fig. 5

miR-545 directly targets KDM4B mRNA. a putative binding site between miR-545 and KDM4B predicted on Starbase; b KDM4B expression in OC and the paired normal tissues determined by IHC staining (n = 60, paired t test, *p < 0.05); c mRNA expression of KDM4B in the tissues determined by RT-qPCR (n = 60, paired t test, **p < 0.01); d a negative correlation between miR-545 and KDM4B expression (Pearson’s correlation analysis, miR-545 vs. KDM4B mRNA: r = − 7607, p < 0.0001; miR-545 VS IHC staining score of KDM4B: r = − 0.8507, p < 0.0001); e KDM4B expression in SV40, OV-90 and ES-2 cells measured by RT-qPCR (one-way ANOVA, #p < 0.05); f-g mRNA (f) and protein (g) expression of KDM4B in OV-90 and ES-2 cells after miR-545 mimic administration measured by RT-qPCR and western blot analysis, respectively (relative to GAPDH, one-way ANOVA, &p < 0.05); h binding relationship between miR-545 and KDM4B validated by a dual luciferase reporter gene assay (two-way ANOVA, &p < 0.05). Representative images are provided. Data were collected from three independent experiments and expressed as mean ± SD

Back to article page